Biotech & Pharma

BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration

26 sec read3 views0 listens

Bristol Myers Squibb (BMS) and Hengrui Pharma have entered a $15.2 billion collaboration to co-develop 13 early-stage programs in oncology, hematology, and immunology, combining BMS’s global capabilities with Hengrui’s discovery expertise. This partnership is crucial for both companies as it helps BMS diversify its pipeline amid the loss of patent exclusivity on key drugs, while enhancing Hengrui's global presence.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

ASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Ends

Terry Flotte, outgoing president of ASGCT, highlights initiatives aimed at improving access to rare disease cell and gene therapies. Key among these is the launch of CGTxchange, an AI-enabled platform designed to facilitate the continuation of promis...

Ali Nemati

Biotech & Pharma11 hours ago24 sec read

Synthesizing a Natural Sunscreen and Antioxidant in E. coli

Researchers at Jiangnan University have engineered E. coli to produce gadusol, a UV-protective compound with antioxidant properties, increasing yield by 93 times compared to natural extraction methods. This development offers a sustainable alternativ...

Ali Nemati

Tech & Gadgets13 hours ago27 sec read

Altman forced to confront claims at OpenAI trial that he's a prolific liar

Sam Altman testified at the OpenAI trial, facing claims that he is a liar and defending the company's shift towards profit-oriented operations. This testimony is crucial as it directly addresses Musk’s allegations about OpenAI deviating from its orig...

Ali Nemati

Cybersecurity17 hours ago28 sec read

EU won't ban LGBTQ 'conversion therapy' but will push states to act

The European Union will not ban LGBTQ conversion therapy but will urge member states to take action against such practices. This approach reflects the EU's legal limitations and its preference for national-level legislation, impacting efforts to prot...

Ali Nemati

AI & Machine Learning2 days ago1m & 1 s read

Google DeepMind's powerful AI co-mathematician

Key Highlights from The Rundown AI Newsletter DeepMind's New Language Model, AlphaCode 2.0 Achievement: DeepMind’s new language model has achieved a score of 95% on the HumanEval benchmark. Comparison to GPT-4: This places it just behind Anthropic C...

Ali Nemati

BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration

Related Articles

ASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Ends

Synthesizing a Natural Sunscreen and Antioxidant in E. coli

Altman forced to confront claims at OpenAI trial that he's a prolific liar

EU won't ban LGBTQ 'conversion therapy' but will push states to act

Google DeepMind's powerful AI co-mathematician